Want to see ALUR full AI Analyst Report?
Top Page
Allurion Technologies
(OTC:ALUR)
Select Model
Select Model
Rating:40Underperform
Price Target:
$1.00
▼(-42.86% Downside)
Action:Reiterated
Date:09/06/26
The score is driven primarily by very weak financial performance (sharp revenue contraction, outsized losses, ongoing cash burn, and negative equity), reinforced by bearish technicals with price far below key moving averages and negative MACD. Valuation is difficult to justify with negative earnings, and recent board resignations add incremental governance risk.
Positive Factors
Differentiated Balloon Platform
A swallowable, temporary balloon that avoids endoscopy or surgery offers a differentiated treatment pathway within weight management. Its simpler procedure may support provider adoption and patient access, while the associated digital and monitoring program can reinforce a broader care offering over time.
Negative Factors
Sustained Revenue Contraction
Revenue has contracted sharply over several years, reaching $12.6 million TTM from $64.2 million in 2022. This reduces scale, limits the resources available for commercial investment, and makes it harder for the company to absorb fixed costs or establish a durable growth trajectory.
Read all positive and negative factors
Positive Factors
Negative Factors
Differentiated Balloon Platform
A swallowable, temporary balloon that avoids endoscopy or surgery offers a differentiated treatment pathway within weight management. Its simpler procedure may support provider adoption and patient access, while the associated digital and monitoring program can reinforce a broader care offering over time.
Read all positive factors
Allurion Technologies (ALUR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.12M
Dividend YieldN/A
Average Volume (3M)2.41K
Price to Earnings (P/E)―
Beta (1Y)2.88
Revenue Growth-55.49%
EPS Growth21.55%
CountryUS
Employees40
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-56.40
Shares Outstanding1,000,417
10 Day Avg. Volume1,679
30 Day Avg. Volume2,408
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-0.12
Price to Sales (P/S)0.61
P/FCF Ratio-0.32
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-20.25
Revenue Forecast (FY)$13.70M
Allurion Technologies Business Overview & Revenue Model
Company Description
Allurion Technologies Inc. is dedicated to combating obesity by offering a comprehensive weight management ecosystem designed for individuals with excess weight. At the core of its solution is the Allurion Program, featuring the innovative Allurio...
How the Company Makes Money
Allurion primarily makes money by selling its weight-loss solution to healthcare providers and/or clinics that deliver the program to patients. Revenue is generated from the commercial sale of the Allurion Balloon (a single-use device for each tre...
Allurion Technologies Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.60M | 15.23M | 32.11M | 53.47M | 64.21M | 38.24M |
| Gross Profit | 6.64M | 9.57M | 21.50M | 41.50M | 50.73M | 29.19M |
| EBITDA | -39.46M | -27.70M | -22.17M | -69.03M | -32.28M | -8.01M |
| Net Income | -33.35M | -28.75M | -26.15M | -80.61M | -37.74M | -12.39M |
Balance Sheet | ||||||
| Total Assets | 13.99M | 15.77M | 32.81M | 71.71M | 51.37M | 39.35M |
| Cash, Cash Equivalents and Short-Term Investments | 5.06M | 5.41M | 15.38M | 38.04M | 7.68M | 25.84M |
| Total Debt | 29.45M | 29.04M | 37.92M | 41.86M | 59.53M | 26.14M |
| Total Liabilities | 91.91M | 92.96M | 110.79M | 142.20M | 83.68M | 73.64M |
| Stockholders Equity | -77.91M | -77.19M | -77.98M | -70.49M | -32.31M | -34.28M |
Cash Flow | ||||||
| Free Cash Flow | -22.70M | -28.95M | -42.91M | -65.59M | -48.53M | -15.24M |
| Operating Cash Flow | -22.70M | -28.95M | -42.30M | -63.98M | -46.98M | -14.33M |
| Investing Cash Flow | 0.00 | 0.00 | -611.00K | -1.61M | -1.55M | -912.00K |
| Financing Cash Flow | 7.34M | 18.97M | 20.21M | 95.99M | 30.54M | 28.95M |
Allurion Technologies Technical Analysis
Negative
1.75
Price Trends
3.65
Negative
7.27
Negative
12.61
Negative
Market Momentum
-0.87
Positive
20.53
Positive
1.16
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALUR, the sentiment is Negative. The current price of 1.75 is below the 20-day moving average (MA) of 2.23, below the 50-day MA of 3.65, and below the 200-day MA of 12.61, indicating a bearish trend. The MACD of -0.87 indicates Positive momentum. The RSI at 20.53 is Positive, neither overbought nor oversold. The STOCH value of 1.16 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ALUR.
Allurion Technologies Risk Analysis
Allurion Technologies disclosed 88 risk factors in its most recent earnings report. Allurion Technologies reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Allurion Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $7.95M | -0.02 | -62.28% | ― | ― | 43.06% | |
45 Neutral | $3.47M | -0.07 | -734.86% | ― | 60.75% | 71.34% | |
44 Neutral | $10.86M | -0.30 | -565.55% | ― | -28.53% | 47.55% | |
44 Neutral | $8.28M | -0.04 | -210.99% | ― | -9.18% | 33.16% | |
43 Neutral | $12.30M | -3.44 | -78.94% | ― | 3.68% | 36.91% | |
40 Underperform | $1.12M | -0.13 | 44.17% | ― | -55.49% | 21.55% |
* Healthcare Sector Average
ALUR
Allurion Technologies
1.12
-31.58
-96.57%
IRIX
Iridex
0.70
-0.68
-49.28%
SINT
Sintx Technologies
1.63
-2.96
-64.49%
CODX
Co-Diagnostics
1.16
-8.15
-87.54%
XAIR
Beyond Air
3.53
-62.67
-94.67%
NVNO
enVVeno Medical
11.44
-15.11
-56.92%
Allurion Technologies Corporate Events
Business Operations and StrategyExecutive/Board Changes
Allurion Technologies Restructures Board After Director Resignations
Negative
Aug 24, 2026
On August 17, 2026, Allurion Technologies director Krishna Gupta, a Class I board member, resigned from the board and the Nominating and Corporate Governance Committee, effective the same day. Two days later, on August 19, 2026, Class III director...
Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and ComplianceShareholder MeetingsStock Split
Allurion Technologies Executes Reverse Stock Split to Regain Listing
Neutral
Jun 17, 2026
Allurion Technologies, Inc., a metabolically focused weight-loss medtech company, said that shareholders approved a reverse stock split at the 2025 annual meeting held on Dec. 18, 2025. The board later set the ratio at 1-for-15, reducing the compa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.